Evolving Treatment Paradigms and Recent Data Updates in HR+/HER2- Breast Cancer

Following the 2023 ASCO Annual Meeting, experts on HR+/HER2- breast cancer discuss the evolving treatment landscape and data updates on frontline and later-line therapies.

EP. 1: Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

EP. 2: Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

EP. 3: Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer

July 4th 2023

The expert panel reviews data updates on neoadjuvant therapy in HR+/HR2- early breast cancer and discusses the role of CDK4/6 inhibition in this setting.

EP. 4: Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer

July 4th 2023

A discussion on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in HR+/HER2- breast cancer.

EP. 5: Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer

July 11th 2023

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

EP. 6: Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer

July 11th 2023

VK Gadi, MD, PhD, shares his strategies for managing adverse events related to abemaciclib in the treatment of HR+/HER2- breast cancer.

EP. 7: Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer

July 18th 2023

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

EP. 8: CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.

EP. 9: Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials

July 25th 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

EP. 10: The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings

July 25th 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

EP. 11: Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice

August 1st 2023

Timothy Pluard, MD, discusses recent data from an age-based subgroup analysis of RIGHT Choice, which compares the efficacy of combination ribociclib/ET versus chemotherapy in the first-line treatment of HR+/HER2- advanced breast cancer.

EP. 12: Potential Approaches to Treatment Switching in HR+/HER2- mBC

August 1st 2023

Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.

EP. 13: Addressing Disease Progression on ET: Data Updates and Ongoing Trials

August 8th 2023

A focused discussion on trials that may address disease progression on first-line therapy, including those on ET and CDK4/6 inhibitor rechallenge and novel combination strategies.

EP. 14: HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway

August 8th 2023

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

EP. 15: Biomarker Testing Practices in HR+/HER2- Breast Cancer

August 15th 2023

Experts on HR+/HER2- breast cancer discuss biomarker testing approaches, including sampling considerations and timing of testing.

EP. 16: Data Updates on Sacituzumab Govitecan

August 15th 2023

Dr Gadi discusses recent data updates on the TROP-2–directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG), including analyses performed in patients with HER2-low disease.

EP. 17: Practical Considerations for ADC Selection in HR+/HER2- mBC

August 22nd 2023

Panelists share clinical insight into how to approach treatment selection among ADCs in HR+/HER2- metastatic breast cancer both now and in the future, given the currently available options and additional ADCs in development.

EP. 18: Looking Towards The Future of HR+/HER2- Breast Cancer

August 22nd 2023

The expert panel discusses ongoing research and offers closing thoughts on the future of HR+/HER2- breast cancer treatment.